Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aromatase is the rate-limiting enzyme in estrogen biosynthesis and its expression in breast adipose stromal cells is hypothesized to drive the growth of breast tumors and confer resistance to endocrine therapy in obese postmenopausal women.
|
30851382 |
2019 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To block the growth of breast tumors, aromatase inhibitors (AIs) are employed to bind and inhibit aromatase in order to lower the amount of estrogen produced in the body.
|
30190660 |
2018 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> This study was undertaken to conduct a comprehensive investigation of the role of DNA damage repair (DDR) defects in poor outcome ER<sup>+</sup> disease.<b>Experimental Design:</b> Expression and mutational status of DDR genes in ER<sup>+</sup> breast tumors were correlated with proliferative response in neoadjuvant aromatase inhibitor therapy trials (discovery dataset), with outcomes in METABRIC, TCGA, and Loi datasets (validation datasets), and in patient-derived xenografts.
|
29793947 |
2018 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Endocrine therapy is the mainstay of treatment for hormone-responsive breast tumors (about 70% of all breast cancers) and implies the use of selective estrogen receptor modulators and aromatase inhibitors.
|
30513833 |
2018 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Effects of Neonicotinoid Pesticides on Promoter-Specific Aromatase (CYP19) Expression in Hs578t Breast Cancer Cells and the Role of the VEGF Pathway.
|
29701941 |
2018 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The aromatase inhibitors (AIs) are considered - as first-line treatment for estrogen receptor-positive (ER<sup>+</sup>) breast tumors, in postmenopausal women.
|
29791862 |
2018 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We investigated whether ER and PR-B interactions were present in breast tumours and associated with clinical parameters including response to aromatase inhibitors.
|
30410061 |
2018 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We also report that DVL enters the nucleus and localizes to at least two different CYP19A1 promoters (pII and I.4) previously reported to drive overexpression in breast tumors and to a very distal CYP19A1 placental promoter (I.1) that remains poorly characterized.
|
30479694 |
2018 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Nearly 75% of breast tumors express estrogen receptor (ER), and will be treated with endocrine therapy, such as selective estrogen receptor modulator (SERM), tamoxifen, or aromatase inhibitors.
|
28396978 |
2017 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.
|
28112739 |
2017 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, when combined with MSI/LOH in AR, ERβ and CYP19 genes, we were able to detect significant associations with the GSTP1 wild-type genotype in PR (progesterone receptor) negative breast cancers or the CYP17 wild-type genotype in ER (estrogen receptor) and PR-negative breast tumors.
|
28692125 |
2017 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We present data that letrozole, an extensively used aromatase inhibitor in the treatment of estrogen receptor-positive breast tumors in postmenopausal women, may be potentially used in the treatment of glioblastomas.
|
25695958 |
2015 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.
|
24923427 |
2014 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model.
|
25023195 |
2014 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
As tamoxifen via GPER induced aromatase expression also in CAFs, this pathway may be involved in promoting aggressive behavior of breast tumors in response to tamoxifen treatment.
|
24928526 |
2014 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Local estrogen production by aromatase plays a more important role than circulating estradiol in breast tumor promotion.
|
25182769 |
2014 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkers.
|
24669750 |
2014 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In elucidating a novel mechanism by which androgens, through DAX-1, inhibit aromatase expression in breast cancer cell lines, these findings reinforce the theory of androgen- opposing estrogen-action, opening new avenues for therapeutic intervention in estrogen-dependent breast tumors.
|
23846226 |
2013 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This study is the first to identify HIF-1α as a modulator of PII-driven aromatase expression in human breast tumor-associated stroma and provides a novel mechanism for estrogen regulation in obesity-related, post-menopausal breast cancer.
|
23566437 |
2013 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
|
23493347 |
2013 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.
|
23342035 |
2013 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Chromatin immunoprecipitation identified ER genomic binding activity in estrogen-deprived cells and primary breast tumors treated with aromatase inhibitors.
|
22049316 |
2011 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Several recent studies demonstrated activity of aromatase P450 (Cyp19), a key enzyme that plays critical role in E2 synthesis in breast tumors.
|
19800002 |
2010 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of aromatase in breast cancer tissue is driven by different promoters than those in noncancer tissues; thus, suppression of aromatase expression in cancer tissues through the down-regulation of breast tumor-specific promoters would reduce the side effects associated with whole-body suppression of estrogen biosynthesis by AIs.
|
20534486 |
2010 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here we comparatively analyzed for the first time aromatase, estrogen 4-hydroxylase (CYP1B1) and fatty acid synthase immunohistochemical expression in breast tumors obtained from 12 BRCA1 mutations carriers and 22 non-carriers.
|
19083124 |
2009 |